Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

6 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe CPUO.

The design includes 4 periods, for a total duration of up to 60 weeks:

  • Screening period: up to 4 weeks.
  • Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo
  • Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24.
  • Safety follow-up period: 4 weeks of treatment-free safety follow-up.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

180

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Novartis Pharmaceuticals
  • Número de teléfono: +41613241111

Ubicaciones de estudio

      • CABA, Argentina, C1181ACH
        • Reclutamiento
        • Novartis Investigative Site
    • Buenos Aires
      • Caba, Buenos Aires, Argentina, C1119ACN
        • Reclutamiento
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DBS
        • Reclutamiento
        • Novartis Investigative Site
    • Ontario
      • Hamilton, Ontario, Canadá, L8L 3C3
        • Reclutamiento
        • Novartis Investigative Site
    • Quebec
      • Québec, Quebec, Canadá, G1W 4R4
        • Reclutamiento
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 03722
        • Reclutamiento
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 07804
        • Reclutamiento
        • Novartis Investigative Site
    • Gyeonggi-do
      • Ansan, Gyeonggi-do, Corea del Sur, 15355
        • Reclutamiento
        • Novartis Investigative Site
    • Alabama
      • Cullman, Alabama, Estados Unidos, 35058
        • Reclutamiento
        • Aller Vie Health-Cullman
        • Investigador principal:
          • John Anderson
        • Contacto:
    • Florida
      • Miami, Florida, Estados Unidos, 33126
    • Georgia
      • Savannah, Georgia, Estados Unidos, 31406
        • Reclutamiento
        • Aeroallergy Research Laboratories
        • Investigador principal:
          • Brad Goodman
        • Contacto:
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Reclutamiento
        • Dawes Fretzin Clinical Rea Group
        • Investigador principal:
          • Kenneth Dawes
        • Contacto:
      • New Albany, Indiana, Estados Unidos, 47150
        • Reclutamiento
        • Southern IN Clinical Trials
        • Contacto:
        • Investigador principal:
          • Megan Landis
    • New York
      • The Bronx, New York, Estados Unidos, 10455
        • Reclutamiento
        • Equity Medical
        • Investigador principal:
          • Michael Cameron
        • Contacto:
    • Ohio
      • Boardman, Ohio, Estados Unidos, 44512
        • Reclutamiento
        • Optima Research-Boardman
        • Investigador principal:
          • Patrick Shannon
        • Contacto:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15241
        • Reclutamiento
        • Allergy and Clinical Immunology Associates
        • Investigador principal:
          • Michael Palumbo
        • Contacto:
    • South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29420
        • Reclutamiento
        • National Allergy and Asthma Research LLS
        • Investigador principal:
          • John T Ramey
        • Contacto:
    • Texas
      • Pflugerville, Texas, Estados Unidos, 78660
        • Reclutamiento
        • Austin Inst for Clinical Research
        • Investigador principal:
          • Edward Lain
        • Contacto:
    • Fukuoka
      • Kitakyushu, Fukuoka, Japón, 8078556
        • Reclutamiento
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japón, 2400013
        • Reclutamiento
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto, Kumamoto, Japón, 8620950
        • Reclutamiento
        • Novartis Investigative Site
    • Osaka
      • Habikino, Osaka, Japón, 5838588
        • Reclutamiento
        • Novartis Investigative Site
      • Sakai, Osaka, Japón, 5938324
        • Reclutamiento
        • Novartis Investigative Site
    • Tokyo
      • Tachikawa, Tokyo, Japón, 1900023
        • Reclutamiento
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

  • Participant must be ≥ 18 years of age, at the time of signing the informed consent.
  • Participants with chronic pruritus for at least 4 months prior to screening.
  • Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
  • Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
  • Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
  • Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
  • Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
  • The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
  • Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.

Key Exclusion Criteria:

  • Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
  • Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
  • Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected HIV infection.
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
  • History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Remibrutinib

Remibrutinib film coated tablets

Oral administration of remibrutinib

Otros nombres:
  • LOU064
Experimental: Placebo followed by remibrutinib

Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

Oral administration of remibrutinib

Otros nombres:
  • LOU064

Oral administration of matching placebo.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)
Periodo de tiempo: Baseline, Week 12

The WI-NRS is a patient-reported outcome (PRO) instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Baseline, Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of participants achieving ≥4 point reduction from baseline in WI NRS
Periodo de tiempo: Baseline, Week 4

The WI-NRS is a PRO instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Baseline, Week 4
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Periodo de tiempo: Week 12

The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

Week 12
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Periodo de tiempo: Week 24

The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

Week 24
Change from baseline in Pruritus-related Sleep Disturbance Numerical Rating Scale (SD-NRS)
Periodo de tiempo: Week 12

The SD-NRS is a PRO instrument used to assess the degree of sleep disturbance caused by pruritus (itch). The score range is from 0 (No sleep disturbance) to 10 (Worst possible sleep disturbance). Higher scores indicate greater sleep disturbance due to pruritus.

Week 12
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Up to Week 52

Number of participants with AEs and SAEs.

Up to Week 52

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

24 de agosto de 2026

Finalización primaria (Estimado)

19 de diciembre de 2029

Finalización del estudio (Estimado)

15 de abril de 2030

Fechas de registro del estudio

Enviado por primera vez

7 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

7 de julio de 2026

Publicado por primera vez (Actual)

13 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • CLOU064R12301
  • 2025-524497-41 (Otro identificador: EU CTIS number)
  • 2025 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir